Amneal Pharmaceuticals, Inc. (AMRX)

About Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

As of November 3, 2026, Amneal Pharmaceuticals, Inc. (AMRX) stock slipped to $20.22, down 1.08% (-$0.22) versus the previous close. On the day, shares have traded between $19.68 and $20.80. That puts AMRX in the upper third of its 52-week range of $10.92 to $21.68. Amneal Pharmaceuticals, Inc. operates in the pharmaceutical preparations space and carries a market capitalization of roughly $7.12 billion, with about 910.8K shares changing hands.

Latest AMRX news

• NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales ViewYahoo Finance· Nov 3, 10:15 AM ET
• JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales ViewYahoo Finance· Nov 3, 10:12 AM ET
• Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone RevenuesYahoo Finance· Nov 3, 9:59 AM ET
• CRSP's Q3 Loss Wider Than Expected, Sales Beat EstimatesYahoo Finance· Nov 3, 9:24 AM ET
• Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to SayYahoo Finance· Nov 3, 8:30 AM ET
• Amneal (NASDAQ:AMRX) beats expectations in strong Q3 2026, full-year outlook slightly exceeds expectationsYahoo Finance· Nov 3, 6:30 AM ET
• Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top EstimatesYahoo Finance· Nov 3, 6:25 AM ET
• Amneal Reports Third Quarter 2026 Financial ResultsYahoo Finance· Nov 3, 6:00 AM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want AMRX headlines, alerts and AI research in one place? Create a free account →

• https://www.marketbeat.com/earnings/reports/2026-11-3-amneal-pharmaceuticals-inc-stock-1/ $AMRX Amneal Pharmaceuticals Earnings Transcript

  @EarningsInsider· Nov 3, 10:03 AM ET

• $AMRX reported earnings this morning before the open and beat EPS estimates: $0.26 adjusted EPS vs $0.2374 expected, according to Stock Meadow.

  @shoc24· Nov 3, 9:28 AM ET· Bullish

• $AMRX Q3 '26 Earnings Results & Recap Amneal increased full year 2026 net revenue guidance to $3.15B$3.25B, adjusted EBITDA to $800M$815M, and adjusted diluted EPS to $1.04$1.08; operating cash flow guidance was updated to $325M$375M.

  @StocktwitsEarnings· Nov 3, 7:45 AM ET

• $AMRX $LLY $REGN GLP-1 medications are the single largest driver of Lilly's explosive financial growth.$QQQ

  @inspector_gadget86· Oct 30, 8:24 PM ET· Bullish

• $AMRX $LLY $REGN exceptionally strong third-quarter earnings report driven by blockbuster demand for its GLP-1 medications.

  @inspector_gadget86· Oct 30, 8:23 PM ET· Bullish

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →